Enact Holdings, Inc.
US ˙ NasdaqGS ˙ US29249E1091

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for William Meury. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at William Meury har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:INCY / Incyte Corporation Chief Executive Officer, Director 36.101
US:SNDX / Syndax Pharmaceuticals, Inc. Director 90.000
US:KRTX / Karuna Therapeutics, Inc. President and CEO, Director 0
US:ACT / Enact Holdings, Inc. EVP & Chief Commercial Officer 0
EVP - Sales and Marketing 0
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af William Meury. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb ACT / Enact Holdings, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACT / Enact Holdings, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

ACT / Enact Holdings, Inc. Insider Trades
Insidersalg ACT / Enact Holdings, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACT / Enact Holdings, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2018-02-14 AGN Meury William 25.079 157,1800 25.079 157,1800 3.941.917 313
2018-02-14 AGN Meury William 1.200 157,6000 1.200 157,6000 189.120
2018-02-14 AGN Meury William 1.700 158,7800 1.700 158,7800 269.926
2018-02-14 AGN Meury William 2.400 159,8200 2.400 159,8200 383.568
2018-02-14 AGN Meury William 1.000 161,1000 1.000 161,1000 161.100
2018-02-14 AGN Meury William 4.700 162,2200 4.700 162,2200 762.434
2018-02-14 AGN Meury William 7.200 163,0400 7.200 163,0400 1.173.888
2018-02-14 AGN Meury William 2.000 164,6200 2.000 164,6200 329.240
2018-02-14 AGN Meury William 13.600 165,1600 13.600 165,1600 2.246.176
2017-12-01 AGN Meury William 9.272 173,8900 9.272 173,8900 1.612.308
2017-12-01 AGN Meury William 2.535 173,8900 2.535 173,8900 440.811
2014-11-26 ACT Meury William 4.550 269,1443 4.550 269,1443 1.224.607

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

ACT / Enact Holdings, Inc. Insider Trades
Insiderkøb SNDX / Syndax Pharmaceuticals, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACT / Enact Holdings, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SNDX / Syndax Pharmaceuticals, Inc. Insider Trades
Insidersalg SNDX / Syndax Pharmaceuticals, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACT / Enact Holdings, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2023-08-02 SNDX Meury William 35.000 20,4556 35.000 20,4556 715.946 82 11.3900 -317.296 -44,32
2023-08-02 SNDX Meury William 24.000 20,4563 24.000 20,4563 490.951
2023-08-02 SNDX Meury William 24.000 20,4547 24.000 20,4547 490.913

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SNDX / Syndax Pharmaceuticals, Inc. Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af William Meury som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2025-07-02 2025-07-02 4 INCY INCYTE CORP
Common Stock
A - Award 36.101 36.101
2025-02-07 2025-02-05 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
A - Award 25.000 90.000 38,46
2024-03-18 2024-03-18 4 KRTX Karuna Therapeutics, Inc.
Common Stock
D - Sale to Issuer -19.037 0 -100,00 330,00 -6.282.210
2024-03-18 2024-03-18 4 KRTX Karuna Therapeutics, Inc.
Common Stock
D - Sale to Issuer -10.342 19.037 -35,20 330,00 -3.412.860 6.282.210
2024-02-09 2024-02-07 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
A - Award 17.000 65.000 35,42
2023-12-29 2023-12-28 4 KRTX Karuna Therapeutics, Inc.
Common Stock
F - Taxes -8.694 29.379 -22,84 316,30 -2.749.912 9.292.578
2023-08-03 2023-08-02 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale -24.000 48.000 -33,33 20,45 -490.913 981.826
2023-08-03 2023-08-02 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 24.000 72.000 50,00 9,47 227.280 681.840
2023-08-03 2023-08-02 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale -24.000 48.000 -33,33 20,46 -490.951 981.902
2023-08-03 2023-08-02 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 24.000 72.000 50,00 7,88 189.120 567.360
2023-08-03 2023-08-02 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale -35.000 48.000 -42,17 20,46 -715.946 981.869
2023-08-03 2023-08-02 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 35.000 83.000 72,92 7,11 248.850 590.130
2023-02-03 2023-02-02 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
A - Award 16.000 48.000 50,00
2023-01-05 2023-01-03 4 KRTX Karuna Therapeutics, Inc.
Common Stock
A - Award 38.073 38.073
2022-02-03 2022-02-02 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
A - Award 16.000 32.000 100,00
2021-02-05 2021-02-03 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
A - Award 16.000 16.000
2020-05-11 2020-05-08 4 AGN Allergan plc
Performance Stock Units
D - Sale to Issuer -26.506 0 -100,00
2020-05-11 2020-05-08 4 AGN Allergan plc
Stock Options
D - Sale to Issuer -12.304 0 -100,00
2020-05-11 2020-05-08 4 AGN Allergan plc
Stock Options
D - Sale to Issuer -21.621 0 -100,00
2020-05-11 2020-05-08 4 AGN Allergan plc
Stock Options
D - Sale to Issuer -10.089 0 -100,00
2020-05-11 2020-05-08 4 AGN Allergan plc
Stock Options
D - Sale to Issuer -16.081 0 -100,00
2020-05-11 2020-05-08 4 AGN Allergan plc
Stock Options
D - Sale to Issuer -509 0 -100,00
2020-05-11 2020-05-08 4 AGN Allergan plc
Stock Options
D - Sale to Issuer -1.246 0 -100,00
2020-05-11 2020-05-08 4 AGN Allergan plc
Stock Options
D - Sale to Issuer -1.387 0 -100,00
2020-05-11 2020-05-08 4 AGN Allergan plc
Stock Options
D - Sale to Issuer -1 0 -100,00
2020-05-11 2020-05-08 4 AGN Allergan plc
Stock Options
D - Sale to Issuer -19.278 0 -100,00
2020-05-11 2020-05-08 4 AGN Allergan plc
Restricted Stock Units
D - Sale to Issuer -25.201 0 -100,00
2020-05-11 2020-05-08 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
D - Sale to Issuer -7.434 0 -100,00
2020-04-07 2020-04-03 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -855 32.635 -2,55 175,71 -150.232 5.734.296
2020-03-04 2020-03-02 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
A - Award 21.667 33.490 183,26 193,84 4.199.931 6.491.702
2020-02-14 2020-02-12 4 SNDX Syndax Pharmaceuticals Inc
Stock Option (Right to Buy)
A - Award 24.000 24.000
2020-01-02 2019-12-31 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -1.504 11.823 -11,29 191,17 -287.520 2.260.203
2019-06-12 2019-06-10 4 SNDX Syndax Pharmaceuticals Inc
Stock Option (Right to Buy)
A - Award 24.000 24.000
2019-04-05 2019-04-03 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -871 13.327 -6,13 145,71 -126.913 1.941.877
2019-01-03 2018-12-31 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -1.531 14.198 -9,73 133,66 -204.633 1.897.705
2018-09-27 2018-09-25 4 SNDX Syndax Pharmaceuticals Inc
Stock Option (Right to Buy)
A - Award 35.000 35.000
2018-05-21 2018-05-17 4 AGN Allergan plc
Non-Qualified Options to Purchase Common Stock
M - Exercise -19.785 0 -100,00
2018-05-21 2018-05-17 4 AGN Allergan plc
Incentive Stock Option
M - Exercise -1.467 0 -100,00
2018-05-21 2018-05-17 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
S - Sale X -24.425 15.729 -60,83 154,59 -3.775.861 2.431.546
2018-05-21 2018-05-17 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
M - Exercise X 19.785 40.154 97,13 68,11 1.347.556 2.734.889
2018-05-21 2018-05-17 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
M - Exercise X 1.467 20.369 7,76 68,11 99.917 1.387.333
2018-04-05 2018-04-03 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -819 18.902 -4,15 164,74 -134.922 3.113.915
2018-02-16 2018-02-14 4 AGN Allergan plc
Non-Qualified Options to Purchase Common Stock
M - Exercise -17.381 0 -100,00
2018-02-16 2018-02-14 4 AGN Allergan plc
Incentive Stock Option
M - Exercise -1.510 0 -100,00
2018-02-16 2018-02-14 4 AGN Allergan plc
Non-Qualified Options to Purchase Common Stock
M - Exercise -2.765 0 -100,00
2018-02-16 2018-02-14 4 AGN Allergan plc
Incentive Stock Option
M - Exercise -1.957 0 -100,00
2018-02-16 2018-02-14 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
S - Sale -13.600 19.721 -40,82 165,16 -2.246.176 3.257.120
2018-02-16 2018-02-14 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
S - Sale -2.000 33.321 -5,66 164,62 -329.240 5.485.303
2018-02-16 2018-02-14 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
S - Sale -7.200 35.321 -16,93 163,04 -1.173.888 5.758.736
2018-02-16 2018-02-14 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
S - Sale -4.700 42.521 -9,95 162,22 -762.434 6.897.757
2018-02-16 2018-02-14 4 AGN Allergan plc
Ordinary Shares, par vaule $0.0001
S - Sale -1.000 47.221 -2,07 161,10 -161.100 7.607.303
2018-02-16 2018-02-14 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
S - Sale -2.400 48.221 -4,74 159,82 -383.568 7.706.680
2018-02-16 2018-02-14 4 AGN Allergan plc
Ordinary Shares, par vaule $0.0001
S - Sale -1.700 50.621 -3,25 158,78 -269.926 8.037.602
2018-02-16 2018-02-14 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
S - Sale -1.200 52.321 -2,24 157,60 -189.120 8.245.790
2018-02-16 2018-02-14 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
S - Sale -25.079 53.521 -31,91 157,18 -3.941.917 8.412.431
2018-02-16 2018-02-14 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
M - Exercise 17.381 78.600 28,39 66,20 1.150.622 5.203.320
2018-02-16 2018-02-14 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
M - Exercise 1.510 61.219 2,53 66,20 99.962 4.052.698
2018-02-16 2018-02-14 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
M - Exercise 2.765 59.709 4,86 51,07 141.209 3.049.339
2018-02-16 2018-02-14 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
M - Exercise 1.957 56.944 3,56 51,07 99.944 2.908.130
2018-01-02 2017-12-29 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -1.611 55.410 -2,83 163,58 -263.527 9.063.968
2017-12-04 2017-12-01 4 AGN Allergan plc
Incentive Stock Option
M - Exercise -2.535 0 -100,00
2017-12-04 2017-12-01 4 AGN Allergan plc
Non-Qualified Options to Purchase Common Stock
M - Exercise -9.272 0 -100,00
2017-12-04 2017-12-01 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
S - Sale -2.535 57.021 -4,26 173,89 -440.811 9.915.382
2017-12-04 2017-12-01 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
S - Sale -9.272 59.556 -13,47 173,89 -1.612.308 10.356.193
2017-12-04 2017-12-01 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
M - Exercise 2.535 68.828 3,82 78,88 199.961 5.429.153
2017-12-04 2017-12-01 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
M - Exercise 9.272 66.293 16,26 78,88 731.375 5.229.192
2017-10-30 2017-10-26 4 AGN Allergan plc
Performance Based Restricted Share Unit
M - Exercise -9.321 0 -100,00
2017-10-30 2017-10-26 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
M - Exercise 9.321 57.021 19,54
2017-05-16 2017-05-15 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -587 47.700 -1,22 228,22 -133.965 10.886.094
2017-04-04 2017-04-03 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
A - Award 8.835 48.287 22,39 237,68 2.099.903 11.476.854
2017-02-14 2016-12-08 4 AGN Allergan plc
Non-qualified Stock Option (Right to Buy)
M - Exercise -11.807 0 -100,00
2017-02-14 2016-12-08 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -9.414 39.452 -19,26 188,47 -1.774.257 7.435.518
2017-02-14 2016-12-08 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
M - Exercise 11.807 48.866 31,86 109,12 1.288.380 5.332.258
2016-05-17 2016-05-15 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -510 37.059 -1,36 223,35 -113.908 8.277.128
2016-05-17 2016-05-15 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -713 37.569 -1,86 223,35 -159.249 8.391.036
2016-03-04 2014-07-01 4/A AGN Allergan plc
Ordinary Shares, par value $0.0001
A - Award 47.165 47.165
2015-12-28 2015-12-23 4 AGN Allergan plc
Ordinary shares, par value $0.0001
G - Gift -423 70.100 -0,60
2015-05-19 2015-05-15 4 ACT Actavis plc
Ordinary Shares, par value $0.0001
F - Taxes -671 70.523 -0,94 296,60 -199.019 20.917.122
2015-05-19 2015-05-15 4 ACT Actavis plc
Ordinary Shares, par value $0.0001
F - Taxes -773 71.194 -1,07 296,60 -229.272 21.116.140
2015-05-19 2015-05-15 4 ACT Actavis plc
Ordinary Shares, par value $0.0001
F - Taxes -437 71.967 -0,60 296,60 -129.614 21.345.412
2015-04-02 2015-04-01 4 ACT Actavis plc
Ordinary Shares, par value $0.0001
F - Taxes -1.788 72.404 -2,41 296,19 -529.588 21.445.341
2015-04-02 2015-04-01 4 ACT Actavis plc
Ordinary Shares, par value $0.0001
F - Taxes -3.848 74.192 -4,93 296,19 -1.139.739 21.974.928
2014-12-22 2014-12-18 4 ACT Actavis plc
Ordinary Shares, par value $0.0001
G - Gift -98 78.040 -0,13
2014-12-10 2014-12-06 4 ACT Actavis plc
Ordinary Shares, par value $0.0001
F - Taxes -2.469 78.138 -3,06 266,59 -658.211 20.830.809
2014-12-10 2014-12-05 4 ACT Actavis plc
Ordinary Shares, par value $0.0001
F - Taxes -1.332 80.607 -1,63 266,59 -355.098 21.489.020
2014-12-01 2014-11-26 4 ACT Actavis plc
Stock Option (Right to Buy)
M - Exercise -7.083 0 -100,00
2014-12-01 2014-11-26 4 ACT Actavis plc
Ordinary Shares, par value $0.0001
S - Sale -4.550 81.939 -5,26 269,14 -1.224.607 22.053.415
2014-12-01 2014-11-26 4 ACT Actavis plc
Ordinary Shares, par value $0.0001
M - Exercise 7.083 86.489 8,92 90,06 637.895 7.789.199
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Performance Stock Units
D - Sale to Issuer -13.310 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Performance Stock Units
D - Sale to Issuer -24.000 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Performance Stock Units
A - Award 13.310 13.310
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Performance Stock Units
A - Award 24.000 24.000
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -26.053 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -1.079 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -45.780 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -2.640 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -21.362 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -2.938 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -34.049 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -1 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -41.892 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -3.108 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -36.802 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -3.198 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -5.855 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -4.145 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -19.632 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -5.368 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -25.000 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -2.352 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Stock Option (Right to Buy)
D - Sale to Issuer -12.648 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Restricted Stock
D - Sale to Issuer -35.590 0 -100,00
2014-07-03 2014-07-01 4 FRX Forest Laboratories, LLC
Common Stock
D - Sale to Issuer -55.882 0 -100,00
2014-07-03 2014-07-01 4 ACT Actavis plc
Stock Option (Right to Buy)
A - Award 19.278 19.278
2014-07-03 2014-07-01 4 ACT Actavis plc
Performance-Based Restricted Stock Unit
A - Award 21.184 21.184
2014-07-03 2014-07-01 4 ACT Actavis plc
Stock Option (Right to Buy)
A - Award 12.814 12.814
2014-07-03 2014-07-01 4 ACT Actavis plc
Stock Option (Right to Buy)
A - Award 22.868 22.868
2014-07-03 2014-07-01 4 ACT Actavis plc
Stock Option (Right to Buy)
A - Award 11.476 11.476
2014-07-03 2014-07-01 4 ACT Actavis plc
Stock Option (Right to Buy)
A - Award 16.081 16.081
2014-07-03 2014-07-01 4 ACT Actavis plc
Stock Option (Right to Buy)
A - Award 21.253 21.253
2014-07-03 2014-07-01 4 ACT Actavis plc
Stock Option (Right to Buy)
A - Award 18.892 18.892
2014-07-03 2014-07-01 4 ACT Actavis plc
Stock Option (Right to Buy)
A - Award 4.723 4.723
2014-07-03 2014-07-01 4 ACT Actavis plc
Stock Option (Right to Buy)
A - Award 11.807 11.807
2014-07-03 2014-07-01 4 ACT Actavis plc
Stock Option (Right to Buy)
A - Award 11.807 11.807
2014-07-03 2014-07-01 4 ACT Actavis plc
Stock Option (Right to Buy)
A - Award 7.084 7.084
2014-07-03 2014-07-01 4 ACT Actavis plc
Ordinary Shares, par value $0.0001
A - Award 79.406 79.406
2014-05-19 2014-05-15 4 FRX FOREST LABORATORIES INC
Common Stock
F - Taxes -891 91.472 -0,96 92,23 -82.177 8.436.463
2014-05-16 2014-05-13 4 FRX FOREST LABORATORIES INC
Stock Option (Right to Buy)
A - Award 27.132 27.132
2014-05-16 2014-05-13 4 FRX FOREST LABORATORIES INC
Common Stock
A - Award 8.519 92.363 10,16
2013-12-10 2013-12-07 4 FRX FOREST LABORATORIES INC
Common Stock
F - Taxes -3.698 83.844 -4,22 56,34 -208.327 4.723.352
2013-12-10 2013-12-06 4 FRX FOREST LABORATORIES INC
Common Stock
F - Taxes -4.747 87.542 -5,14 56,34 -267.422 4.931.679
2013-12-09 2013-12-05 4 FRX FOREST LABORATORIES INC
Common Stock
F - Taxes -2.038 92.289 -2,16 55,86 -113.853 5.155.725
2013-05-23 2013-05-21 4 FRX FOREST LABORATORIES INC
Stock Option (Right to Buy)
A - Award 48.420 48.420
2013-05-23 2013-05-21 4 FRX FOREST LABORATORIES INC
Common Stock
A - Award 13.300 94.327 16,41
2013-05-17 2013-05-15 4 FRX FOREST LABORATORIES INC
Common Stock
F - Taxes -889 82.805 -1,06 38,88 -34.560 3.219.044
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Stock Option (Right to Buy)
M - Exercise -11.350 34.050 -25,00
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Stock Option (Right to Buy)
M - Exercise -15.000 10.000 -60,00
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -500 81.916 -0,61 35,89 -17.945 2.939.965
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -200 82.416 -0,24 35,88 -7.176 2.957.086
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -200 82.616 -0,24 35,86 -7.172 2.962.610
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -400 82.816 -0,48 35,85 -14.340 2.968.954
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -400 83.216 -0,48 35,84 -14.336 2.982.461
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -600 83.616 -0,71 35,83 -21.498 2.995.961
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -1.300 84.216 -1,52 35,82 -46.566 3.016.617
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -3.445 85.516 -3,87 35,81 -123.365 3.062.328
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -2.400 88.961 -2,63 35,80 -85.920 3.184.804
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -600 91.361 -0,65 35,79 -21.474 3.269.810
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -100 91.961 -0,11 35,78 -3.578 3.290.365
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -5.419 92.061 -5,56 35,75 -193.729 3.291.181
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -9.048 97.480 -8,49 35,65 -322.561 3.475.162
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -1.738 106.528 -1,61 35,64 -61.942 3.796.658
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Common Stock
M - Exercise 11.350 108.266 11,71 30,00 340.443 3.247.439
2013-02-08 2013-02-06 4 FRX FOREST LABORATORIES INC
Common Stock
M - Exercise 15.000 96.916 18,31 24,12 361.800 2.337.614
2012-12-11 2012-12-08 4 FRX FOREST LABORATORIES INC
Common Stock
F - Taxes -2.706 81.916 -3,20 35,78 -96.821 2.930.954
2012-12-11 2012-12-07 4 FRX FOREST LABORATORIES INC
Common Stock
F - Taxes -4.488 84.622 -5,04 35,78 -160.581 3.027.775
2012-12-10 2012-12-06 4 FRX FOREST LABORATORIES INC
Common Stock
F - Taxes -3.608 89.110 -3,89 35,82 -129.257 3.192.366
2012-12-07 2012-12-05 4 FRX FOREST LABORATORIES INC
Common Stock
F - Taxes -1.988 92.718 -2,10 35,87 -71.310 3.325.795
2012-05-09 2012-05-07 4 FRX FOREST LABORATORIES INC
Stock Option (Right to Buy)
A - Award 24.300 24.300
2012-05-09 2012-05-07 4 FRX FOREST LABORATORIES INC
Common Stock
A - Award 7.300 94.706 8,35
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -100 87.406 -0,11 32,20 -3.220 2.814.910
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -600 87.506 -0,68 32,20 -19.320 2.817.693
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -500 88.106 -0,56 32,19 -16.095 2.836.132
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -600 88.606 -0,67 32,18 -19.308 2.851.341
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -600 89.206 -0,67 32,17 -19.302 2.869.757
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -701 89.806 -0,77 32,16 -22.544 2.888.161
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -1.643 90.507 -1,78 32,15 -52.822 2.909.800
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -896 92.150 -0,96 32,14 -28.797 2.961.701
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -1.400 93.046 -1,48 32,13 -44.982 2.989.568
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -100 94.446 -0,11 32,11 -3.211 3.032.661
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -1.100 94.546 -1,15 32,10 -35.310 3.034.927
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -939 95.646 -0,97 32,09 -30.133 3.069.280
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -200 96.585 -0,21 32,08 -6.416 3.098.447
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -2.500 96.785 -2,52 32,07 -80.175 3.103.895
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -200 99.285 -0,20 32,06 -6.413 3.183.574
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -4.300 99.485 -4,14 32,06 -137.858 3.189.489
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -2.544 103.785 -2,39 32,06 -81.548 3.326.828
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -6.288 106.329 -5,58 32,05 -201.530 3.407.844
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -2.300 112.617 -2,00 32,04 -73.704 3.608.812
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -500 114.917 -0,43 32,04 -16.021 3.682.228
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -2.762 115.417 -2,34 32,04 -88.494 3.697.961
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -2.026 118.179 -1,69 32,03 -64.893 3.785.273
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -100 120.205 -0,08 32,02 -3.202 3.848.964
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -536 120.305 -0,44 32,01 -17.157 3.850.963
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -413 120.841 -0,34 32,00 -13.216 3.866.924
2012-01-19 2012-01-18 4 FRX FOREST LABORATORIES INC
Common Stock
S - Sale -8.000 121.254 -6,19 32,00 -256.000 3.880.128
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)